3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

Authors: Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, Jose Robles-Zurita, Mark P Saunders, Andrew H Briggs, Jim Cassidy, Niels Henrik Hollander, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Sarah Pearson, Ashita Waterston, Louise Medley, Charles Wilson, Richard Ellis, Sharadah Essapen, Amandeep S Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet Wasan, James Paul

Source: Health Technology Assessment, Vol 23, Iss 64 (2019)

Subject Terms: oxaliplatin, capecitabine, disease-free survival, chemotherapy, adjuvant, quality-adjusted life-years, colorectal neoplasms, fluorouracil, randomised controlled trial, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://doaj.org/toc/1366-5278; https://doaj.org/toc/2046-4924

Access URL: https://doaj.org/article/4215111445164519a465163178fd46e0